A. Orfano, A. Cisse, Y. Guo, L. Han, N. Fikadu, L. G. Thiam, A. Ba, R. Li, M. N. Pouye, K. Mangou, A. J. Moore, S. D. Sene, F. Diallo, E. M. Ngom, B. Sadio, A. Mbengue, C. Membi, B. Ngasala, T. Bazie, F. A. Some, N. Olson, S. D. Patel, L. Shapiro, S. Parikh, B. D. Foy, M. Cappello, I. Vigan-Womas, Z. Premji, R. K. Dabire, J.-B. Ouedraogo, Z. Sheng, A. K. Bei
Transmission-blocking vaccines (TBVs) are a promising strategy to reduce malaria transmission by targeting parasite stages within the mosquito. However, parasite genetic diversity may limit vaccine efficacy. We used next-generation amplicon deep sequencing to identify non-synonymous single nucleotide polymorphisms (SNPs) in Pfs25 from 184 Plasmodium falciparum isolates from Senegal, Tanzania, Ghana, and Burkina Faso. Prioritized SNPs were introduced into P. falciparum via CRISPR-Cas9. For the G116C variant, gametocyte development was evaluated by microscopy and qPCR, and mosquito infectivity was assessed by SMFAs. We identified 26 SNPs, including 24 novel variants. Functional assays showed that the Pfs25 G116C mutation did not affect gametocyte development or exflagellation. SMFA showed no significant differences in oocyst prevalence or intensity between mutant and WT parasites. These findings highlight the importance of integrating genetic surveillance with functional validation to guide the development of effective transmission blocking interventions